EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tatva Chintan Pharma Chem EBITDA Margin % Related Terms
Tatva Chintan Pharma Chem EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:TATVA vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Tatva Chintan Pharma Chem's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tatva Chintan Pharma Chem EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Tatva Chintan Pharma Chem's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tatva Chintan Pharma Chem's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tatva Chintan Pharma Chem (NSE:TATVA) has a EBITDA Margin % of 20.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tatva Chintan Pharma Chem and its competitors. This is near median its historical median of 19.21. Over the past decade, Tatva Chintan Pharma Chem's EBITDA Margin % has ranged from 9.54 to 27.05. According to the industry distribution chart, Tatva Chintan Pharma Chem ranks #322 out of 1580 companies in the Chemicals industry, placing it in the top 20.4%.
Is Tatva Chintan Pharma Chem's EBITDA Margin % too high?
Tatva Chintan Pharma Chem's current EBITDA Margin % of 20.71% is near median its 10-year median of 19.21. Over the past 10 years, this metric has ranged from a low of 9.54 to a high of 27.05. The Chemicals industry median EBITDA Margin % is 9.63. Tatva Chintan Pharma Chem's value of 20.71% is 115.2% above this industry median. Based on the distribution chart, Tatva Chintan Pharma Chem ranks #322 out of 1580 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Tatva Chintan Pharma Chem ranks #322 out of 1580 companies for EBITDA Margin %. This places Tatva Chintan Pharma Chem in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.63. Tatva Chintan Pharma Chem's value of 20.71% is 115.2% above this benchmark. Historically, Tatva Chintan Pharma Chem's own EBITDA Margin % has ranged from 9.54 to 27.05 over the past decade. While the company's 10-year median is 19.21 vs. the industry median of 9.63, Tatva Chintan Pharma Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,580 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tatva Chintan Pharma Chem's current EBITDA Margin % of 20.71% is 115.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tatva Chintan Pharma Chem and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tatva Chintan Pharma Chem's current EBITDA Margin % is 20.71%, which is near median its own 10-year median of 19.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,453.22, compared to a current price of ₹1,196.00 — trading 17.7% below its estimated fair value. The current EBITDA Margin % is 20.71%, which is near median its 10-year median of 19.21 and 115.2% above the Chemicals industry median of 9.63. Tatva Chintan Pharma Chem's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current EBITDA Margin % is 20.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be undervalued.
The current stock price of ₹1,196.00 is trading 17.7% below its estimated GF Value™ of ₹1,453.22.
GuruFocus considers Tatva Chintan Pharma Chem to be Modestly Undervalued.
Key valuation signals for NSE:TATVA:
EBITDA Margin %: 20.71% (near median its 10-year median of 19.21)
GF Value™: ₹1,453.22 vs. price of ₹1,196.00 (17.7% below fair value)
Industry Position: 115.2% above the Chemicals median (#322 of 1580)
No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
81GF Score
Get the complete analysis for NSE:TATVA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TATVA has been successfully added to your 
